atrasentan
Phase 3- Indications
- IgA Nephropathy, Rare kidney diseases
Company intelligence / Profile preview
Chinook Therapeutics
Seattle, Washington, United Statesnovartis.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Chinook has two Phase 3 assets in development for IgA Nephropathy: atrasentan (an oral endothelin A receptor antagonist) with pivotal readout expected in Q3 2023, and zigakibart/BION-1301 (an anti-APRIL monoclonal antibody) which entered Phase 3 in July 2023. Atrasentan has shown significant reductions in proteinuria in clinical trials.
- Therapeutic areas
- Rare DiseasesNephrology
- Modalities
- Small moleculesMonoclonal antibodiesPrecision medicines
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
AbbVie (in-licensed atrasentan)
Beyond the preview
Go deeper on Chinook Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chinook Therapeutics.